TherapeuticsMD, Inc.
Progesterone formulations having a desirable PK profile
Last updated:
Abstract:
This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
Status:
Grant
Type:
Utility
Filling date:
9 Mar 2017
Issue date:
12 Nov 2019